Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ)verified

BIOVF

Price:

$35.25

Market Cap:

$118.34B

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, ...[Read more]

Industry

Drug Manufacturers - Specialty & Generic

IPO Date

2021-01-08

Stock Exchange

OTC

Ticker

BIOVF

The Enterprise Value as of December 2025 (TTM) for Swedish Orphan Biovitrum AB (publ) (BIOVF) is 130.89B

According to Swedish Orphan Biovitrum AB (publ)’s latest financial reports and current stock price. The company's current Enterprise Value is 130.89B. This represents a change of 14.19% compared to the average of 114.62B of the last 4 quarters.

Swedish Orphan Biovitrum AB (publ) (BIOVF) Historical Enterprise Value (quarterly & annually)

How has BIOVF Enterprise Value performed in the past?

The mean historical Enterprise Value of Swedish Orphan Biovitrum AB (publ) over the last ten years is 64.81B. The current 130.89B Enterprise Value has changed 20.09% with respect to the historical average. Over the past ten years (40 quarters), BIOVF's Enterprise Value was at its highest in in the September 2024 quarter at 129.44B. The Enterprise Value was at its lowest in in the June 2016 quarter at 27.32B.

Quarterly (TTM)
Annual

Average

64.81B

Median

64.28B

Minimum

30.36B

Maximum

124.06B

Swedish Orphan Biovitrum AB (publ) (BIOVF) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Swedish Orphan Biovitrum AB (publ) Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 69.21%

Maximum Annual Enterprise Value = 124.06B

Minimum Annual Increase = -14.53%

Minimum Annual Enterprise Value = 30.36B

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2024124.06B17.33%
2023105.73B41.93%
202274.49B11.12%
202167.04B2.49%
202065.41B3.56%
201963.16B22.95%
201851.37B69.21%
201730.36B-0.98%
201630.66B-14.53%
201535.87B68.27%

Swedish Orphan Biovitrum AB (publ) (BIOVF) Average Enterprise Value

How has BIOVF Enterprise Value performed in the past?

The current Enterprise Value of Swedish Orphan Biovitrum AB (publ) (BIOVF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

101.43B

5-year avg

87.35B

10-year avg

64.81B

Swedish Orphan Biovitrum AB (publ) (BIOVF) Enterprise Value vs. Peers

How is BIOVF’s Enterprise Value compared to its peers?

Swedish Orphan Biovitrum AB (publ)’s Enterprise Value is greater than Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (97.14B), greater than CSPC Pharmaceutical Group Limited (72.86B), greater than Orion Oyj (8.74B), greater than Recordati Industria Chimica e Farmaceutica S.p.A. (9.85B), less than Eisai Co., Ltd. (1.25T), less than Eisai Co., Ltd. (1.25T), greater than CSPC Pharmaceutical Group Limited (72.86B), greater than Eurofins Scientific SE (13.85B), less than Bangkok Dusit Medical Services Public Company Limited (309.87B), greater than Grifols, S.A. (15.61B),

Build a custom stock screener for Swedish Orphan Biovitrum AB (publ) (BIOVF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Swedish Orphan Biovitrum AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Swedish Orphan Biovitrum AB (publ) (BIOVF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Swedish Orphan Biovitrum AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Swedish Orphan Biovitrum AB (publ)'s Enterprise Value?

What is the highest Enterprise Value for Swedish Orphan Biovitrum AB (publ) (BIOVF)?

What is the 3-year average Enterprise Value for Swedish Orphan Biovitrum AB (publ) (BIOVF)?

What is the 5-year average Enterprise Value for Swedish Orphan Biovitrum AB (publ) (BIOVF)?

How does the current Enterprise Value for Swedish Orphan Biovitrum AB (publ) (BIOVF) compare to its historical average?